- Home
- QNST vs AUPH Comparison
QNST vs AUPH Comparison
Compare QNST & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNST
- AUPH
- Stock Information
- Founded
- QNST 1999
- AUPH 1993
- Country
- QNST United States
- AUPH Canada
- Employees
- QNST N/A
- AUPH N/A
- Industry
- QNST Business Services
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- QNST Consumer Discretionary
- AUPH Health Care
- Exchange
- QNST Nasdaq
- AUPH Nasdaq
- Market Cap
- QNST 1.1B
- AUPH 1.1B
- IPO Year
- QNST 2010
- AUPH 1999
- Fundamental
- Price
- QNST $18.00
- AUPH $8.05
- Analyst Decision
- QNST Strong Buy
- AUPH Strong Buy
- Analyst Count
- QNST 7
- AUPH 2
- Target Price
- QNST $28.86
- AUPH $11.50
- AVG Volume (30 Days)
- QNST 487.6K
- AUPH 1.4M
- Earning Date
- QNST 05-07-2025
- AUPH 05-01-2025
- Dividend Yield
- QNST N/A
- AUPH N/A
- EPS Growth
- QNST N/A
- AUPH N/A
- EPS
- QNST N/A
- AUPH 0.04
- Revenue
- QNST $928,723,000.00
- AUPH $235,133,000.00
- Revenue This Year
- QNST $80.76
- AUPH $11.86
- Revenue Next Year
- QNST $9.11
- AUPH $24.96
- P/E Ratio
- QNST N/A
- AUPH $201.00
- Revenue Growth
- QNST 68.98
- AUPH 33.97
- 52 Week Low
- QNST $15.20
- AUPH $4.71
- 52 Week High
- QNST $26.27
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- QNST 40.19
- AUPH 44.83
- Support Level
- QNST $18.49
- AUPH $7.93
- Resistance Level
- QNST $19.52
- AUPH $8.73
- Average True Range (ATR)
- QNST 0.84
- AUPH 0.23
- MACD
- QNST 0.14
- AUPH -0.04
- Stochastic Oscillator
- QNST 40.39
- AUPH 15.00
About QNST QuinStreet Inc.
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.